Divine Intervention Episode 545: USMLE Step 2CK/3 Rapid Review Series 116

Divine Intervention Episode 545: USMLE Step 2...

Up next

DIP Ep 640: USMLE Free 86 Series 2 (Q11-20, for Step 2/3)

In this episode, I continue my thorough review of the SPEX Qs referenced in Ep 639. Really, really high yield stuff here for the USMLE Step 2CK and Step 3 exams. spex-practice-test Audio Download 

DIP Ep 639: USMLE Free 86 Series 1 (Q1-10, for Step 2/3)

The USMLEs have a series of very good “Free 120” style questions they call “SPEX” questions that are freely available on their website. It’s a collection of 86 very high yield questions. The goal with this series is to walk through all 86 of them (like I did for the free 120) wit ...  Show more

Recommended Episodes

Episode 00: Introduction
Super High Yield Anesthesia!

Welcome to the introductory episode of the Super High Yield Anesthesia Podcast! In this episode we will talk about who this podcast is for, the structure of the podcast, ideas for future episodes, and a few disclaimers. I look forward to discussing anesthesia with you in the comi ...  Show more

Episode 079: Heme Consult Series: When anticoagulation fails, Part 1
The Fellow on Call: The Heme/Onc Podcast

It’s time for another Heme Consult series, this time focusing on another common question we see in the hospital and in clinic: “is this anticoagulation failure?”

In this two-part series, we bre ...

  Show more

Episode 077: Management of relapsed diffuse large B-cell lymphoma (DLBCL) - part 1
The Fellow on Call: The Heme/Onc Podcast

In our last episode, we discussed our approach to primary refractory DLBCL. This week, we start our conversation about relapsed DLBCL! This is an important and complex discussion, so we have split it into two episodes to help you follow a ...

  Show more

Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
The Fellow on Call: The Heme/Onc Podcast

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

  Show more